**Core tip:** Several pharmacokinetic studies have raised concerns regarding the interaction between proton pump inhibitors (PPIs) and immunosuppressive drugs in transplant patients. Whether the adverse effects of PPIs have a clinical significance in kidney transplant recipients remains unclear. We performed this meta-analysis to assess the risk of adverse effects in kidney transplant recipients on PPI compared with those without PPI exposure. We demonstrate that PPI use is not associated with significant risks of higher acute rejection, graft loss, or 1-year mortality. However, PPI use is associated with 1.56-fold increased risk of hypomagnesemia. Thus, future studies are needed to assess the impact of PPIs on long-term outcomes.

INTRODUCTION
============

Proton pump inhibitors (PPIs) are commonly prescribed after transplantation for prophylaxis against peptic ulcer disease and for treatment of gastro-esophageal reflux disease or dyspepsia. Prolonged exposure to this class of medication has been shown to be associated with kidney dysfunction\[[@B1],[@B2]\], as well as other non-renal adverse outcomes, including hypomagnesemia\[[@B3]\], fracture\[[@B4]\], or dementia\[[@B5]\] in the general population. The risk of kidney dysfunction associated with PPIs is particularly concerning to kidney transplant recipients who are already at risk for acute kidney injury.

Mycophenolate mofetil (MMF) is an antimetabolite that is commonly used as part of the maintenance immunosuppression in kidney transplant recipients\[[@B6]\]. MMF is a prodrug that is hepatically metabolized to the active compound mycophenolic acid (MPA) after oral administration. MPA exerts its immunosuppressive effects by reversibly inhibiting the de novo synthesis of purine nucleotides, leading to reduced proliferation of B- and T-cell lymphocytes, induction of activated T lymphocyte apoptosis, and downregulation of adhesion molecule expression, resulting in lower leukocyte trafficking and recruitment\[[@B7]\]. Because gastrointestinal discomfort is a common side effect of MMF, PPIs are commonly prescribed to alleviate the sym-ptoms. However, pharmacokinetic studies\[[@B8]-[@B12]\] have shown that PPIs reduce the absorption of MMF and lower the exposure to MPA presumably by its potent inhibition of gastric acidification compared with another class of acid suppressant, the H2-receptor antagonists\[[@B13],[@B14]\]. Randomized controlled trials\[[@B15],[@B16]\] and observational studies\[[@B17]-[@B19]\] have also shown that reduced exposure to MPA is associated with higher risk of acute rejection and overall worse allograft outcome in kidney transplant recipients. However, the clinical significance of this drug interaction in kidney transplant recipients is unknown. Several studies\[[@B20],[@B21]\] have shown a possible increased risk of acute rejection with PPI exposure whereas others have not\[[@B22]-[@B24]\].

Some studies\[[@B25],[@B26]\] have shown that concurrent PPI can increase tacrolimus drug concentration, leading to higher risk of toxicity through cytochrome or p-glycoprotein inhibition in patients with certain Cytochrome P450 2C19 (CYP2C19) and/or CYP3A5 genotypes. However, this is not expected to increase the risk of rejection, but calcineurin inhibitor toxicity may lead to renal dysfunction. Other commonly used immunosuppressive drugs are not known to have significant interaction with PPIs.

PPI may also interfere with magnesium absorption in the gastrointestinal tract, causing hypomagnesemia\[[@B3]\]. The mechanism of renal dysfunction related to PPIs is not clear although acute interstitial nephritis (AIN) associated with PPIs has been purposed\[[@B1],[@B2]\].

Therefore, we conducted this systematic review and meta-analysis to investigate the adverse outcomes in kidney transplant recipients on PPI compared with those without PPI exposure. The outcomes of interest include biopsy-proven acute rejection, graft loss, kidney dysfunction, hypomagnesemia, and overall mortality.

MATERIALS AND METHODS
=====================

Search strategy
---------------

The protocol for this meta-analysis is registered with PROSPERO, No. CRD420-18115676. PRISMA statement guidelines were followed for conducting and reporting meta-analysis data\[[@B27]\]. A systematic review was conducted in MEDLINE, EMBASE, and Cochrane databases from inception to October 2018 to identify studies that evaluated adverse effects of PPIs in kidney transplant recipients by using the search terms "kidney transplant" and "proton pump inhibitor," as described in the online supplementary data without any language restriction. References of selected articles were also manually searched for additional studies.

Inclusion criteria
------------------

Studies were eligible for this meta-analysis if the following inclusion criteria were met: (1) Randomized controlled trial, cohort (either prospective or retrospective), case--control study or cross-sectional study published as an original study to evaluate the outcomes of kidney transplantation in patients on PPIs; (2) Odds ratios (ORs), relative risk (RR), hazard ratio (HR), and standardized incidence ratio (SIR) with 95% confidence intervals (CIs) or sufficient raw data to calculate these ratios were provided; and (3) Subjects not on PPIs were used as comparators in cohort and cross-sectional studies.

Study eligibility was independently evaluated by the investigators (BB and CT). Any disagreement was resolved by mutual consensus. The quality of each study was appraised using the Newcastle--Ottawa quality scale\[[@B28]\]. This scale assesses each study in three domains, including the: (1) Representativeness of the subjects; (2) Com-parability between the study groups; and (3) Ascertainment of the exposure of interest for the case--control study and the outcome of interest for the cohort study. The modified version of the Newcastle--Ottawa scale as described by Herzog et al\[[@B29]\] was used for cross-sectional studies.

Review process and data extraction
----------------------------------

The two study investigators independently reviewed the titles and abstracts of all retrieved articles. Articles that apparently did not fulfill the inclusion criteria were excluded. Only potentially relevant articles underwent full-text review to determine eligibility. A standardized data collection form was used to extract the following information from the included studies: First author's name, year of publication, year of study, country where the study was conducted, study design, source of population, number of subjects, baseline characteristics of the subjects, and effect estimates. This data extraction process was performed by both investigators to ensure accuracy.

Statistical analysis
--------------------

All statistical analyses were performed using Comprehensive Meta-analysis version 3 software (Eaglewood, NJ, United States). The pooled RRs of acute rejection, graft loss, hypomagnesemia, and overall mortality in kidney transplant recipients on PPIs compared with subjects not on PPIs were calculated using the generic inverse method of DerSimonian and Laird\[[@B30]\]. The random-effects model was used, given the high likelihood of between-study variance due to the difference in underlying population and methodology. Cochran\'s Q-test, which was supplemented by *I*^2^ statistics, was used to evaluate statistical heterogeneity. *I*^2^ statistics quantify the proportion of the total variation across studies, that is, due to true heterogeneity rather than chance. An *I*^2^ value of 0% to 25% represents insignificant heterogeneity, \> 25% to ≤ 50% represents low heterogeneity, \> 50% to ≤ 75% represents moderate heterogeneity, and \> 75% represents high heterogeneity\[[@B31]\].

RESULTS
=======

The initial search yielded 838 articles, all of which underwent title and abstract review (Figure [1](#F1){ref-type="fig"}). Most of the articles were excluded at this step because they were case reports, letters to the editor, review articles, or interventional studies, which clearly did not fulfill our inclusion criteria. Eighteen studies underwent full-length article review, and four were excluded because they did not include controls or did not report the outcome of interest. Therefore, 14 studies met our inclusion criteria\[[@B20]-[@B24],[@B32]-[@B40]\] and were included in the meta-analysis. The baseline characteristics of the included studies are summarized in Table [1](#T1){ref-type="table"}. These 14 observational studies consisted of 6786 kidney transplant recipients (\> 1907 with PPI exposure and 2528 without PPI exposure).

###### 

Characteristics of included studies

  **Ref.**                          **Country**        **Type**          **Total N**   **Race**                               **Immuno-suppre-ssive regimen**                      **CNI use** **(% Cyclos-porine)**         **PPI**   **No PPI**                                   **Quality Scale[3](#T1FN3){ref-type="table-fn"}**                                     
  --------------------------------- ------------------ ----------------- ------------- -------------------------------------- ---------------------------------------------------- ----------------------------------------- --------- -------------------------------------------- --------------------------------------------------- ----- ------------- ------------- -------
  Patel et al\[[@B32]\] 2012        United States      Retrospec-tive    561           NR                                     Tacroli-mus, MMF, Predni-sone                        0%                                        155       52±13[1](#T1FN1){ref-type="table-fn"}        NR                                                  406   48±14         NR            3-2-2
  Knorr et al\[[@B20]\] 2014        United States      Retrospec-tive    597           52% Black                              rATG, MMF, Tacroli-mus, Predni-sone                  \<3%                                      213       55±12                                        122/91                                              384   55±13         210/174       4-2-3
  van Boekel et al\[[@B22]\] 2014   The Netherlands    Retrospec-tive    202           98.5% Caucasi-an                       Tacroli-mus, MMF. Predni-sone                        0%                                        125       47.7±12.8                                    61.6%/38.4%                                         77    46.7±13.3     66.2%/43.8%   4-2-3
  Van Ende et al\[[@B33]\] 2014     Belgium            Cross-sectional   512           98% Caucasi-an                         Varies                                               47% (tacroli-mus 35 %)                    101       53 ± 13                                      59%/41%                                             411   53 ± 13       59%/41%       4-2-3
  Alhosaini et al\[[@B34]\] 2015    United States      Retrospec-tive    83            59% Caucasi-an, 19% Black              CNI (Tacroli-mus, Cyclospo-rine), MPA, Predni-sone   5/83 (6%)                                 43        54 ± 15.1                                    25/18                                               40    49.7 ± 16.4   24/16         4-2-3
  Sezer et al\[[@B35]\] 2015        Turkey             Retrospec-tive    354           NR                                     NR                                                   NR                                        164       38.6 ±1 0.7                                  NR                                                  96    NR            38.6 ±1 0.7   3-2-2
  Courson et al\[[@B21]\] 2016      United States      Retrospec-tive    286           51% Caucasi-an, 17% Black, 10% Asian   Tacroli-mus, MMF or MPS, early steroid withdra-wal   0%                                        171       56±13                                        118/53                                              115   54±13         88/27         4-2-3
  Patel et al\[[@B23]\] 2017        United States      Retrospec-tive    522           24% Black                              Tacroli-mus, reduced-dose MMF, predni-sone           11/522 (2%) convert-ed to cyclospo-rine   183       54 (44-63)[2](#T1FN2){ref-type="table-fn"}   102/81                                              339   53 (43-60)    219/120       4-2-3
  Shabaka et al\[[@B36]\] 2017      Spain              Cross-sectional   938           NR                                     CNI-based regimen                                    NR                                        NR        NR                                           NR                                                  NR    NR            NR            3-2-2
  Rouse et al\[[@B24]\] 2017        United States      Retrospec-tive    211           55% Caucasi-an, 30% Black              Tacroli-mus, MMF or MPS, Predni-sone                 0%                                        35        55±10.7                                      25/10                                               176   63±14         124/52        4-2-3
  Uludag et al\[[@B37]\] 2017       Turkey             Retrospec-tive    292           NR                                     NR                                                   NR                                        223       36±10                                        129/104                                             69    33±11         42/27         3-2-2
  Kipp et al\[[@B39]\] 2018         United States      Retrospec-tive    819           NR                                     NR                                                   NR                                        404       NR                                           NR                                                  415   NR            NR            3-1-2
  Douwes et al\[[@B40]\] 2018       The Nether-lands   Cross-sectional   706           NR                                     NR                                                   NR                                        NR        53 ± 13                                      57%/43%                                             NR    53 ± 13       57%/43%       3-1-2
  Gomes-Neto et al\[[@B38]\] 2018   The Nether-lands   Cross-sectional   703           NR                                     NR                                                   NR                                        NR        53 ± 13                                      57%/43%                                             NR    53 ± 13       57%/43%       3-1-2

Data expressed as mean ± SD;

Data expressed as Median (Range);

According to the NOS (Newcastle-Ottawa Scale) classification. NR: Not reported; CNI: Calcineurin inhibitor; MMF: Mycophenolate mofetil; MPS: Mycophenolate sodium; MPA: Mycophenolate; rATG: Rabbit antithymocyte globulin; PPI: Proton pump inhibitors.

![Study selection.](WJT-9-35-g001){#F1}

Acute biopsy-proven rejection and graft loss
--------------------------------------------

Table [2](#T2){ref-type="table"} summarizes the findings across the studies that reported allograft outcomes. Definitions of biopsy-proven acute rejection and presumed rejection across included studies are also shown in Supplementary Table S1. Pooled data for acute rejection at ≥ 1 year were available from six studies with 2427 kidney transplant recipients (980 with PPI exposure and 1447 without PPI exposure). No significant association was found between PPI exposure and the risk of biopsy-proven acute rejection at ≥ 1 year (pooled OR = 1.25, 95%CI: 0.82-1.91, *I*^2^ = 55%, Figure [2](#F2){ref-type="fig"}). At 3 mo, acute rejection risk was also not significantly different between the two groups (pooled OR = 1.54, 95%CI: 0.64-3.82). Acute cellular rejection was more common than antibody-mediated rejection (AMR) and the rejection rates were similar between the two groups, except in studies by Courson *et al*\[[@B21]\] and Rouse *et al*\[[@B24]\] which demonstrated higher rates of AMR among the PPI group. The median time to rejection was reported to be similar between the two groups across four studies (approximately 3-4 mo post-transplant). Graft loss at 1 year was also not different between those with and without PPI ex-posure (pooled OR = 1.30, 95%CI: 0.75-2.24, *I*^2^ = 0%, Figure [3](#F3){ref-type="fig"}).

###### 

Acute rejection and graft loss

  **Ref**.                          **Biopsy-proven acute rejection at ⩾ 1 yr (%)**   **Biopsy-proven or presumed rejection at 3 mo (%)**   **Median time to rejection**                        **Antibody mediated rejection (%)**   **Graft loss (%)**
  --------------------------------- ------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- ------------------------------------- --------------------
  Patel et al\[[@B32]\] 2012                                                                                                                                                                                                          
  PPI                               25 (16%)                                          NR                                                    4.1 mo                                              3.3%                                  NR
  No PPI                            60 (15%)                                          NR                                                    3.3 mo                                              3.1%                                  NR
  *P*                               0.69                                              \-                                                    NS                                                  NS                                    \-
  Knorr et al\[[@B20]\] 2014                                                                                                                                                                                                          
  PPI                               32/213 (15%)                                      NR                                                    110 ± 91 d                                          1/32 (3.1%)                           9/213 (4.2%)
  H2A                               46/384 (12%)                                      NR                                                    110 ± 112 d                                         2/46 (4.3%)                           19/384 (4.9%)
  *P*                               0.15                                              \-                                                    1.0                                                 NR                                    0.84
  van Boekel et al\[[@B22]\] 2014                                                                                                                                                                                                     
  PPI                               NR                                                25/125 (20%) BPAR: 13/125 (10.4%)                     NR                                                  NR                                    NR
  H2RA                              NR                                                15/77 (19.5%) BPAR: 7/77 (9.1%)                       NR                                                  NR                                    NR
  *P*                               \-                                                NS                                                    \-                                                  \-                                    \-
  Courson et al\[[@B21]\] 2014                                                                                                                                                                                                        
  PPI                               16/171 (9.4%)                                     NR                                                    116±92 d[1](#T2FN1){ref-type="table-fn"}            5/16 (31%)                            4/171 (2.3%)
  H2RA                              3/115 (2.6%)                                      NR                                                    both                                                0                                     2/115 (1.7%)
  *P*                               0.029                                             \-                                                    NS                                                  0.53                                  1
  Patel et al\[[@B23]\] 2017                                                                                                                                                                                                          
  PPI                               11/183 (19%)                                      12/183 (4.9%)                                         106 (57-286) days[2](#T2FN2){ref-type="table-fn"}   1/11 (9.1%)                           9/183 (4.9%)
  H2RA                              28/339 (14%)                                      9/339 (3.5%)                                          139 (96-339) days                                   2/28 (7.1%)                           8/339 (2.4%)
  *P*                               0.35                                              0.44                                                  0.28                                                NR                                    0.12
  Rouse et al\[[@B24]\] 2017                                                                                                                                                                                                          
  PPI                               5/35 NR                                           NR                                                    2/5 (40%)                                           NR                                    
  H2RA                              26/176                                            NR                                                    NR                                                  3/26 (12%)                            NR
  *P*                               1.0                                               \-                                                    \-                                                  0.03                                  \-
  Uludag et al\[[@B37]\] 2017                                                                                                                                                                                                         
  PPI                               36/233 (15.5%)                                    NR                                                    NR                                                  NR                                    11/233 (4.7%)
  No PPI                            5/69 (7.2%)                                       NR                                                    NR                                                  NR                                    2/69 (2.9%)
  *P*                               0.08                                              \-                                                    \-                                                  \-                                    0.51

Data expressed as mean ± SD;

Data expressed as Median (Range). NR: Not reported; NS: Not significant; H2RA: H2-receptor antagonists; PPI: Proton pump inhibitors.

![Forest plot of all included studies evaluating the risk of biopsy-proven rejection at one year or more in proton pump inhibitors users compared with non-users.](WJT-9-35-g002){#F2}

![Forest plot of all included studies evaluating the risk of graft loss in proton pump inhibitors users compared with non-users.](WJT-9-35-g003){#F3}

Renal function
--------------

All but one study reported no significant short term (3 mo to 1 year) difference in renal function, as summarized in Table [3](#T3){ref-type="table"}. Uludag et al\[[@B37]\], which had the most extended follow-up period of all included studies (median, 109 mo; interquartile range, 82-156 mo), however demonstrated that the serum creatinine level in the PPI group was higher than that in the non-PPI group (1.44 ± 0.99 *vs* 1.24 ± 0.46 mg/dL).

###### 

Renal function

  **Ref**.                     **eGFR**                                            **Cr**                                                             
  ---------------------------- --------------------------------------------------- ------------------- ------ ------------------- ------------------- --------------
  Knorr et al\[[@B20]\]        53.1 ± 20.2[1](#T3FN1){ref-type="table-fn"}         55.1 ± 20.6         0.29   NR                  NR                  \-
  van Boekel et al\[[@B22]\]   49.5 ± 12.3                                         50.7 ± 12.5         NS     1.5 ± 0.4 at 3 mo   1.5 ± 0.4           NS
  Patel et al\[[@B23]\]        49.0 (39.4--63.2)[2](#T3FN2){ref-type="table-fn"}   49.9 (39.3--60.8)   0.78   NR                  NR                  \-
  Uludag et al\[[@B37]\]       \-                                                  \-                  \-     1.49 ± 0.99 mg/dL   1.24 ± 0.46 mg/dL   0.017
  Alhosaini et al\[[@B34]\]    49.4 ± 14.9                                         52.8 ± 14.3         0.29   \-                  \-                  \-
  Kipp et al\[[@B39]\]         NR                                                  NR                  \-     1.896 ± 1.53        1.812 ± 1.25        *P* = 0.4098

Data expressed as mean ± SD;

Data expressed as Median (Range). NR: Not reported; NS: Not significant; eGFR: Estimated glomerular filtration rate; PPI: Proton pump inhibitors.

Hypomagnesemia
--------------

Table [4](#T4){ref-type="table"} summarizes data across eight studies. The risk of hypomagnesemia in the PPI group was significantly higher than in the non-PPI group (pooled OR = 1.56, 95%CI: 1.19-2.05, *I*^2^ = 27%, Figure [4](#F4){ref-type="fig"}) based on three studies. Sezer *et al*\[[@B35]\], Van Ende *et al*\[[@B31]\], and Uludag *et al*\[[@B37]\] did not report a significant difference in the magnesium level between those with and without PPI exposure, whereas Alhosaini *et al*\[[@B34]\] reported a significant difference between the two groups (magnesium: 1.70 ± 0.12 *vs* 1.79 ± 0.17 for those with PPI and without PPI exposure; *P* = 0.006). Gomes-Neto *et al*\[[@B38]\] and Douwes *et al*\[[@B40]\] (who analyzed data from an overlapping set of patients) reported a significant inverse correlation between PPI use and plasma magnesium level. The proportion of hy-pomagnesemia also did not differ between the two groups, but a study by Shabaka *et al*\[[@B36]\] noted that those with PPI exposure seemed to develop significantly more severe hypomagnesemia (defined as magnesium level \< 1.3 mg/dL) compared with those without PPI exposure (21% *vs* 5%).

###### 

Hypomagnesemia

  **Ref.**                     **Serum / Plasma magnesium level**   **Hypomagnesemia**   **Magnesium supplemen-tation**                                                                                                                                              
  ---------------------------- ------------------------------------ -------------------- -------------------------------- ------------------------------------- ----------------------------------- ------------- -------------- ----------------------------------- -------------------------------------------------------------
  Sezer et al\[[@B35]\]        1.5 ± 0.04 mg/dl                     1.7 ± 0.02 mg/dl     *P* \< 0.05                      NR                                    NR                                  NR                           NR                                  NR
  Shabaka et al\[[@B36]\]      NR                                   NR                                                    NR                                    OR 1.55, (95%CI 1.09-2.20)          1                            NR                                  NR
  Kipp et al\[[@B39]\]         NR                                   NR                                                    NR                                    215 (53.1%)                         185 (44.6%)   *P* \< 0.013   NR                                  NR
  Alhosaini et al\[[@B34]\]    1.70 ± 0.12                          1.79 ± 0.17          0.006                            Serum Mg \< 1.8 mg/dL                 33/43                               24/40         *P* \> 0.05    NR                                  Use of Mg supplement: PPI 47% *vs* Non-PPI 21% (*P* = 0.02)
  Serum Mg \< 1.3 mg/dL        9/43 (21%)                           2/40 (5%)            *P* = 0.03                                                                                                                                                                  
  Uludag *et al\[[@B37]\]*     0.728 mmol/L                         *vs* 0.755 mmol/L,   *P* = 0.061                      NR                                    NR                                  NR                           NR                                  NR
  Van Ende et al\[[@B33]\]     NR                                   NR                                                    Serum Mg \< 1.7 mg/dL                 β: −0.84 (0.26; 2.71), *P* = 0.78                                β: −0.84 (0.26; 2.71), *P* = 0.78   NR
  Douwes et al\[[@B40]\]       NR                                   NR                                                    Serum Mg \< 1.8 mg/dL (0.75 mmol/L)   HR 3.25 (1.26-8.39)                 1                            β: -0.08, *P* = 0.046               Mean Mg intake: 330 ± 85 mg/d, (*P* = 0.204)
  Gomes-Neto et al\[[@B38]\]   NR                                   NR                                                    NR                                    β: -0.05, *P* = 0.04                NR                           β: -0.05, *P* = 0.04                NR

^1^Data expressed as mean ± SD; ^2^Data expressed as Median (Range); NR: Not reported; NS: Not significant; PPI: Proton pump inhibitors; Mg: Magnesium.

![Forest plot of all included studies evaluating the risk of hypomagnesemia in PPI users compared with non-users.](WJT-9-35-g004){#F4}

Overall mortality
-----------------

All-cause mortality data were available from five studies (Table [5](#T5){ref-type="table"}), with three studies reporting 1-year survival and two reporting longer-term all-cause mortality. One-year mortality did not significantly differ between PPI and non-PPI use (pooled OR = 1.30, 95%CI: 0.51-3.29, *I*^2^ = 41.4%; Figure [5](#F5){ref-type="fig"}). The two studies that reported long-term mortality outcomes (Douwes *et al*\[[@B40]\] and Gomes-Neto *et al*\[[@B38]\]) seemed to analyze data from a highly overlapping set of patients (*n* = 706 *vs* 703); hence, pooled HR was not calculated. With a median follow-up duration of 5.4 years (range, 4.8-6.1 years) in both studies, the adjusted HRs for all-cause mortality was significantly associated with PPI use (HR = 1.94, 95%CI: 1.32-2.88, and HR = 2.01, 95%CI: 1.43-2.83, re-spectively).

###### 

Mortality

  **Ref**.                     **1-yr mortality**   **Mortality beyond 1 yr (PPI *vs* no PPI)**           
  ---------------------------- -------------------- --------------------------------------------- ------- ----------------------------
  Knorr et al\[[@B20]\]        9/213 (4.2%)         17/384 (4.4%)                                 1       
  Courson et al\[[@B21]\]      3/171 (1.8%)         3/115 (2.6%)                                  0.687   
  Patel et al\[[@B23]\]        6/183 (3.3%)         3/339 (0.9%)                                  0.007   
  Douwes et al\[[@B40]\]       NR                   NR                                                    HR 1.94 (95%CI: 1.32-2.88)
  Gomes-Neto et al\[[@B38]\]   NR                   NR                                                    HR 2.01 (95%CI: 1.43-2.83)

NR: Not reported; NS: Not significant; eGFR: Estimated glomerular filtration rate; PPI: Proton pump inhibitors.

![Forest plot of all included studies evaluating the risk of one-year mortality in PPI users compared with non-users.](WJT-9-35-g005){#F5}

Evaluation for publication bias
-------------------------------

The funnel plots (Supplementary Figure S1 to Figure S4) and Egger's regression asymmetry test were performed and showed no significant publication bias (*P* \> 0.05 for all outcomes).

Sensitivity analysis
--------------------

Sensitivity analysis was performed by excluding one study at a time to investigate the effect of each study on the pooled OR for each outcome assessed. The pooled effect estimate from this sensitivity analysis remained essentially unchanged.

DISCUSSION
==========

This meta-analysis showed no significant association between exposure to PPIs and higher risk of acute biopsy-proven rejection, graft loss, or overall mortality, but a significantly higher risk of hypomagnesemia among those with PPI exposure was noted. No short-term difference in renal function was found between the two groups.

Despite several pharmacokinetic studies that have clearly showed significantly reduced MPA exposure following concomitant administration of PPIs and MMF in both healthy volunteers\[[@B12],[@B41]\] and in immediate post-transplant kidney transplant recipients\[[@B10],[@B11]\], there was no significant association between PPI use and increased risk of acute rejection in our study, suggesting that the effect may not be large enough to be clinically significant. Because none of the included studies reported MPA drug level or direct gastric pH measurement, it is difficult to ascertain whether a significant interaction between PPIs and MMF exists in the real-world setting. Three studies (van Boekel et al\[[@B22]\], Courson et al\[[@B21]\], and Patel et al\[[@B23]\]) reported the total cumulative MMF exposure or mean daily dose between the two groups. In all three studies, despite the PPI group receiving a slightly lower cumulative MMF dose compared to the non-PPI group (non-significant in the study by van Boekel et al\[[@B22]\] and Patel et al\[[@B23]\]; significant in the study by Courson et al\[[@B21]\]), no significant difference in acute rejection was found. Interestingly, in black patients, PPI was found to be significantly associated with a higher risk of acute rejection in one study\[[@B20]\].

Another potential reason for the lack of a significant association between PPI use and acute biopsy-proven rejection is that the majority of the kidney transplant recipients enrolled in the included studies were on tacrolimus, with none or only a small percentage of recipients on cyclosporine. The use of tacrolimus as the cal-cineurin inhibitor instead of cyclosporine may help lower the risk of reduced MPA exposure with PPI use. Cyclosporine, unlike tacrolimus, can reduce the enterohepatic recirculation of MPA in the gastrointestinal tract\[[@B42],[@B43]\], thus further lowering total MPA exposure. The enteric-coated mycophenolate sodium does not appear to have a significant interaction with PPI\[[@B8],[@B41],[@B44]\], unlike MMF.

We did not demonstrate a significant difference in renal function as measured by estimated glomerular filtration rate or serum creatinine between the PPI and the non-PPI group in the short term (3 mo to 1 year). Extrapolating from observational studies in the general population, this is not unexpected as the risk of kidney dysfunction seems to be associated with more prolonged PPI use and may have a long latent period\[[@B1],[@B45]\]. Uludag et al\[[@B37]\] also confirmed this observation by noting a significantly higher serum creatinine level in PPI users compared with non-users at a longer median follow-up of 109 mo.

The risk of hypomagnesemia in the PPI group was significantly higher than that in the non-PPI group in our study. This is consistent with studies in the general population that report hypomagnesemia with prolonged PPI use\[[@B3]\]. The exact mechanism of PPI-induced hypomagnesemia is unknown. Urinary magnesium excretion has been shown to be low in patients with hypomagnesemia related to PPI use\[[@B46]\], suggesting that reduced absorption from the gastrointestinal tract is the main cause. It is hypothesized that the TRMP6 (transient receptor potential melastatin) pathway in gut epithelial cells, which mediates magnesium absorption, is inhibited by the high pH milieu caused by PPI use\[[@B47]\]. This inhibition is more pronounced in certain individuals with additional polymorphisms of the related cellular pathway proteins or other risk factors, which explains why the incidence and degree of hypo-magnesemia vary among PPI users\[[@B47]\]. Some studies have also reported that high-dose oral magnesium supplementation can correct hypomagnesemia associated with PPI\[[@B48]\], suggesting that the paracellular passive absorption in the bowel remains intact.

In kidney transplant recipients, hypomagnesemia has been shown to be associated with various adverse consequences\[[@B49]\]. Low magnesium level has been associated with accelerated decline of allograft function and a higher rate of graft loss in patients with cyclosporine-induced nephropathy\[[@B50]\], consistent with animal studies showing a higher degree of renal tissue fibrosis associated with low magnesium\[[@B51]\] that appears to be partially correctable with magnesium supplementation\[[@B51],[@B52]\]. Hypomagnesemia may also lead to a higher incidence of new-onset diabetes after transplant\[[@B53]\], which is a separate risk factor for allograft loss and overall mortality.

Our study did not show a significant difference in the 1-year overall mortality, as expected, because the risks of acute rejection, graft loss, and kidney dysfunction did not significantly differ between the PPI and non-PPI groups. Only hypomagnesemia was found to be significantly associated with PPI use; hence, this may not be clinically significant to drive a mortality difference at least in the short term. However, Douwes et al\[[@B40]\] and Gomes-Neto et al\[[@B38]\] reported a significant association between PPI use and long-term all-cause mortality despite adjustment for confounders. Furthermore, both studies also showed a significant interaction between PPI use and hypomagnesemia. As noted previously, Uludag et al\[[@B37]\] has also reported significantly worse kidney function in the PPI group with longer follow-up (median, 109 mo). Hypomagnesemia or renal dysfunction may be a late manifestation associated with prolonged exposure to PPIs, which may eventually be clinically significant enough to cause higher mortality. Further studies are needed to clarify this question.

Although we believe the literature review process was rigorous and the included studies were of high quality, this meta-analysis has some limitations. Therefore, the interpretation of the results needs to be performed with caution. First, this meta-analysis is based solely on observational studies. Although this is appropriate for our clinical question, it may be inherently subject to selection bias and unadjusted confounders. Second, certain important baseline characteristics could not be obtained or compared across all studies. Of interest to transplant recipients, comparison of different immunosuppressive regimens, drug level, dosage, and adherence to both immunosuppressive drugs or acid suppressive therapy between the two groups was not possible in most included studies due to either their observational or retrospective design. Third, the definitions of various outcomes of interest varied across studies, such as the cut-off value for hypomagnesemia, definition of severe rejection, or the use of different criteria for the classification of AMR and cell-mediated rejection. Finally, most of the included studies only reported follow-up data for a relatively short-term period (approximately 1 year). Therefore, we cannot rule out the possibility that prolonged exposure of PPIs (longer than a year) may lead to adverse outcomes. Further study is needed to address whether long-term PPI exposure in kidney transplant recipients is associated with worse outcomes.

In conclusion, PPI use was not associated with significant risks of higher acute rejection, graft loss, or 1-year mortality. However, the risk of hypomagnesemia was significantly increased with PPI use.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Adverse renal effects of PPIs are increasingly recognized in clinical practice. Pharmacokinetic studies have also raised concerns regarding the interaction between PPIs and immuno-suppressive drugs in transplant patients. Whether the adverse effects of PPIs have a clinical significance in kidney transplant recipients remains unclear.

Research motivation
-------------------

Proton pump inhibitors are commonly used after transplantation for prophylaxis against peptic ulcer disease and for treatment of gastro-esophageal reflux disease or dyspepsia. Prolonged exposure to this class of medication has been shown to be associated with kidney dysfunction, as well as other non-renal adverse outcomes, including hypomagnesemia, fracture, or dementia in the general population. The clinical significance of this drug interaction in kidney transplant recipients is unknown. Several studies have shown a possible increased risk of acute rejection with PPI exposure whereas others have not.

Research objectives
-------------------

We performed this systematic review and meta-analysis to investigate the adverse outcomes in kidney transplant recipients on PPI compared with those without PPI exposure.

Research methods
----------------

A systematic review was conducted in MEDLINE, EMBASE, and Cochrane databases from inception to October 2018 to identify studies that evaluated adverse effects of PPIs in kidney transplant recipients. The outcomes of interest include biopsy-proven acute rejection, graft loss, kidney dysfunction, hypomagnesemia, and overall mortality. The protocol for this meta-analysis is registered with PROSPERO, No. CRD42018115676.

Research results
----------------

The authors found no significant association between exposure to PPIs and higher risk of acute biopsy-proven rejection, graft loss, or overall mortality, but a significantly 1.56-fold higher risk of hypomagnesemia among those with PPI exposure was noted. No short-term difference in renal function was found between the two groups.

Research conclusions
--------------------

PPI use was not associated with significant risks of higher acute rejection, graft loss, or 1-year mortality. However, the risk of hypomagnesemia was significantly increased with PPI use. In the long-term, PPI use may also be associated with kidney dysfunction and increased overall mortality.

Research perspectives
---------------------

This study demonstrated significant hypomagnesemia in kidney transplant recipients who received PPIs. Since hypomagnesemia is associated with new onset diabetes new-onset diabetes after transplantation, future large-scale clinical studies are needed to assess the impact of PPIs on long-term outcomes.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Manuscript source: Invited manuscript

Peer-review started: February 12, 2019

First decision: March 15, 2019

Article in press: May 14, 2019

Specialty type: Transplantation

Country of origin: United States

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Hibberd AD, Boteon YL S-Editor: Dou Y L-Editor: A E-Editor: Wu YXJ

[^1]: Author contributions: Boonpheng B acquisition of data, analysis and interpretation of data, drafting the article, final approval; Thongprayoon C acquisition of data, analysis and interpretation of data, final approval; Bathini T, Sharma K, and Mao MA interpretation of data, revising the article, final approval; Cheungpasitporn W interpretation of data, revising the article, final approval.

    Corresponding author: Wisit Cheungpasitporn, MD, Assistant Professor, Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, 2500 N. State St., Jackson, MS39216, United States. <wcheungpasitporn@gmail.com>

    Telephone: +1-518-2589978 Fax: +1-507-2667891
